Assembly Biosciences, Inc.

This biotechnology company develops innovative therapies for serious viral diseases. Its pipeline includes several clinical-stage investigational therapies. These include two long-acting helicase-primase inhibitors (HPIs) for recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the hepatitis B virus (HBV) replication cycle. The company also has a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for transplant-related herpesviruses, which is currently undergoing studies to enable a regulatory filing, and additional research programs targeting multiple antiviral targets. In December 2025, Gilead Sciences, Inc. (Gilead) licensed the company's HPI program for recurrent genital herpes, including investigational candidates ABI-1179 (1179) and ABI-5366 (5366), as part of their collaboration. The company's strategy focuses on using its virology research and development expertise to discover and advance next-generation therapeutics for areas with high unmet medical need. Current activities include transitioning the HPI program (5366 and 1179) to Gilead and deciding on a Profit-Share option. For HDV, the company is completing Phase 2 preparation activities and studies for ABI-6250 (6250), with Phase 2 initiation expected in the fourth quarter of 2026. For HBV, the company is evaluating partnering opportunities for ABI-4334 (4334) and has initiated a structured process to find potential partners.